PPTDF:OTC-PeptiDream Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 54.18

Change

0.00 (0.00)%

Market Cap

USD 7.19B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD167.99B 29.71 2.87
CSLLY CSL Limited

N/A

USD96.16B 46.11 26.33
CMXHF CSL Limited

N/A

USD94.62B 45.29 26.33
GNMSF Genmab A/S

N/A

USD28.04B 121.29 3.24
UCBJF UCB SA

N/A

USD19.93B 19.80 17.47
UCBJY UCB SA

N/A

USD19.87B 19.75 17.47
SBMFF Sino Biopharmaceutical Limited

N/A

USD19.71B 31.21 2.97
SBHMY Sino Biopharmaceutical Limited

N/A

USD19.71B 28.00 2.97
IDRSF Idorsia Ltd

N/A

USD5.36B 130.60 N/A
ABCZF Abcam plc

N/A

USD5.21B 57.64 114.95

ETFs Containing PPTDF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.32% 43% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.32% 43% F 55% F
Trailing 12 Months  
Capital Gain 4.86% 41% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.86% 41% F 46% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.28% 43% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.28% 42% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 18.11% 98% A+ 78% C+
Risk Adjusted Return 34.70% 65% D 66% D
Market Capitalization 7.19B 97% A+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 260.99 8% F 3% F
Price/Book Ratio 37.09 16% F 6% F
Price / Cash Flow Ratio 14.92 10% F 13% F
EV/EBITDA 1.65 70% C- 61% D-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 2.53% 59% F 46% F
Return on Assets 11.94% 96% A 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.01 45% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.